
Trevi Therapeutics advances with Haduvio to target chronic cough in lung diseases, eyeing market expansion.
Trevi Therapeutics is leveraging the dual mechanism of its drug Haduvio to treat chronic cough associated with idiopathic pulmonary fibrosis (IPF). The company plans to expand its treatment to other interstitial lung diseases (ILD) and refractory chr...


